Press Releases Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
10.34 ^USD	+0.88%		+1.08%	+68.40%

01/04	Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	MT
01/04	Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting	07/05	AQ
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05	AQ
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04	AQ
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01/04	AQ
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	27/03	AQ
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	13/03	AQ
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	07/03	AQ
Solid Biosciences to Participate at Upcoming Investor Conferences	06/03	AQ
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	16/01	AQ
Solid Biosciences Announces $109 Million Private Placement	08/01	AQ
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference	04/01	AQ
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003	07/12	AQ
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference	22/11	AQ
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	15/11	AQ
Solid Biosciences to Participate at Jefferies London Healthcare Conference	09/11	AQ
Solid Biosciences Provides Third Quarter Business Update and Financial Results	09/11	AQ
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer	02/23/02	AQ
Solid Biosciences to Participate at Upcoming Investor Conferences	20/23/20	AQ
Solid Biosciences to Participate at Upcoming Investor Conferences	05/23/05	AQ
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference	31/23/31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Press Releases

Filters